Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Rating of “Hold” by Analysts

Rezolute, Inc. (NASDAQ:RZLT) has earned an average rating of “Hold” from the twelve research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.6667.

A number of research analysts have issued reports on the stock. Maxim Group set a $4.00 target price on shares of Rezolute in a report on Friday, December 12th. Cantor Fitzgerald cut Rezolute from an “overweight” rating to a “neutral” rating in a report on Thursday, December 11th. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. BTIG Research reaffirmed a “buy” rating and set a $5.00 price target on shares of Rezolute in a research note on Thursday, January 8th. Finally, Citizens Jmp cut shares of Rezolute from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 11th.

Insider Buying and Selling

In related news, CEO Nevan C. Elam bought 32,000 shares of the stock in a transaction on Monday, December 15th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $50,880.00. Following the acquisition, the chief executive officer owned 641,119 shares in the company, valued at $1,019,379.21. This represents a 5.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Daron Evans purchased 40,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average price of $1.77 per share, for a total transaction of $70,800.00. Following the acquisition, the chief financial officer directly owned 415,900 shares of the company’s stock, valued at $736,143. This trade represents a 10.64% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 89,100 shares of company stock worth $150,232. 14.78% of the stock is owned by corporate insiders.

Institutional Trading of Rezolute

Several large investors have recently bought and sold shares of RZLT. BNP Paribas Financial Markets acquired a new stake in Rezolute during the 2nd quarter valued at $25,000. HB Wealth Management LLC purchased a new position in Rezolute in the 4th quarter valued at about $26,000. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Rezolute during the fourth quarter valued at about $29,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Rezolute during the second quarter valued at about $30,000. Finally, Legal & General Group Plc acquired a new position in shares of Rezolute in the second quarter worth about $32,000. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Trading Down 7.6%

Shares of RZLT stock opened at $2.91 on Friday. The stock has a 50 day simple moving average of $4.01 and a 200-day simple moving average of $6.65. The company has a market cap of $269.84 million, a price-to-earnings ratio of -3.13 and a beta of 0.46. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.09. On average, equities analysts forecast that Rezolute will post -0.93 earnings per share for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.